Lv31
228 积分 2025-11-04 加入
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
20天前
已完结
Genetically Stable and Scalable Nanoengineering of Human Primary T Cells via Cell Mechanoporation
21天前
已完结
Vector copy number quality control testing for CAR T-cells: critical validation parameters
21天前
已完结
Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy
21天前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
1个月前
已完结
自体CAR-T细胞治疗药品上市申请药学申报资料常见问题和审评关注要点分析
1个月前
已完结
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
1个月前
已完结
CAR-T细胞治疗产品上市前注册检验的特殊要求及关注点
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已关闭
皖公网安备34019202002308
